Prevalence of sarcopenia in community-dwelling older adults using the updated EWGSOP2 definition according to kidney function and albuminuria : The Screening for CKD among Older People across Europe (SCOPE) study.
Activities of Daily Living
Aged
Aged, 80 and over
Albuminuria
/ diagnosis
Cross-Sectional Studies
Europe
/ epidemiology
Female
Glomerular Filtration Rate
Hand Strength
Humans
Independent Living
Kidney
Male
Prevalence
Prospective Studies
Renal Insufficiency, Chronic
/ diagnosis
Sarcopenia
/ diagnosis
Albuminuria
Chronic kidney disease
EWGSOP2
Estimated glomerular filtration rate
Older adults
Sarcopenia
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
02 10 2020
02 10 2020
Historique:
received:
05
08
2020
accepted:
11
08
2020
entrez:
3
10
2020
pubmed:
4
10
2020
medline:
9
2
2021
Statut:
epublish
Résumé
Loss of muscle mass and function may be more pronounced in older adults with chronic kidney disease (CKD) and with albuminuria. Thus, we investigated the prevalence of sarcopenia among community-dwelling older adults according to kidney function and grade of albuminuria. We also explored differences in the prevalence of sarcopenia according to three different equations for the estimation of glomerular filtration rate (eGFR). A cross-sectional analysis of 1420 community-dwelling older adults (≥75 years old) included in the SCOPE study, a multicenter prospective cohort study, was conducted. Comprehensive geriatric assessment including short physical performance battery (SPPB), handgrip strength test and bioelectrical impedance analysis (BIA) was performed. Sarcopenia was defined using the updated criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2). eGFR was calculated using Berlin Initiative Study (BIS), Chronic Kidney Disease Epidemiological Collaboration (CKD-EPI) and Full Age Spectrum (FAS) equations, and urinary albumin-to-creatinine ratio (ACR) was collected to categorize CKD according to Kidney Disease Improving Global Outcomes guidelines. Median age was 79.5 years (77.0-83.0), 804 (56.6%) were women. Using EWGSOP2 definition, 150 (10.6%) participants met diagnostic criteria for sarcopenia. Moreover, 85 (6%) participants had severe sarcopenia. Sarcopenia was more prevalent in participants with more advanced stages of CKD according to BIS eq. (9.6% in stages 1 and 2 and 13.9% in stages 3a, 3b and 4, p = 0.042), and also according to CKD-EPI (9.8% vs. 14.2%, p = 0.042) and FAS although not reaching statistical signification (9.8% vs. 12.7%, p = 0.119). Thus, differences in prevalence are observed among CKD categories as estimated by different equations. Prevalence of sarcopenia was also higher with increasing albuminuria categories: 9.3% in normoalbuminuric, 13.2% in microalbuminuric and 16.8% in macroalbuminuric participants, (p = 0.019). Sarcopenia is common among community-dwelling older adults, especially among those with more advanced CKD categories, with prevalence estimates differing slightly depending on the equation used for the estimation of eGFR; as well as among those with higher albuminuria categories.
Sections du résumé
BACKGROUND
Loss of muscle mass and function may be more pronounced in older adults with chronic kidney disease (CKD) and with albuminuria. Thus, we investigated the prevalence of sarcopenia among community-dwelling older adults according to kidney function and grade of albuminuria. We also explored differences in the prevalence of sarcopenia according to three different equations for the estimation of glomerular filtration rate (eGFR).
METHODS
A cross-sectional analysis of 1420 community-dwelling older adults (≥75 years old) included in the SCOPE study, a multicenter prospective cohort study, was conducted. Comprehensive geriatric assessment including short physical performance battery (SPPB), handgrip strength test and bioelectrical impedance analysis (BIA) was performed. Sarcopenia was defined using the updated criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2). eGFR was calculated using Berlin Initiative Study (BIS), Chronic Kidney Disease Epidemiological Collaboration (CKD-EPI) and Full Age Spectrum (FAS) equations, and urinary albumin-to-creatinine ratio (ACR) was collected to categorize CKD according to Kidney Disease Improving Global Outcomes guidelines.
RESULTS
Median age was 79.5 years (77.0-83.0), 804 (56.6%) were women. Using EWGSOP2 definition, 150 (10.6%) participants met diagnostic criteria for sarcopenia. Moreover, 85 (6%) participants had severe sarcopenia. Sarcopenia was more prevalent in participants with more advanced stages of CKD according to BIS eq. (9.6% in stages 1 and 2 and 13.9% in stages 3a, 3b and 4, p = 0.042), and also according to CKD-EPI (9.8% vs. 14.2%, p = 0.042) and FAS although not reaching statistical signification (9.8% vs. 12.7%, p = 0.119). Thus, differences in prevalence are observed among CKD categories as estimated by different equations. Prevalence of sarcopenia was also higher with increasing albuminuria categories: 9.3% in normoalbuminuric, 13.2% in microalbuminuric and 16.8% in macroalbuminuric participants, (p = 0.019).
CONCLUSIONS
Sarcopenia is common among community-dwelling older adults, especially among those with more advanced CKD categories, with prevalence estimates differing slightly depending on the equation used for the estimation of eGFR; as well as among those with higher albuminuria categories.
Identifiants
pubmed: 33008317
doi: 10.1186/s12877-020-01700-x
pii: 10.1186/s12877-020-01700-x
pmc: PMC7531109
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
327Subventions
Organisme : Horizon 2020 Framework Programme
ID : 634869
Organisme : Horizon 2020 Framework Programme
ID : 634869
Organisme : Horizon 2020 Framework Programme
ID : 634869
Organisme : Horizon 2020 Framework Programme
ID : 634869
Organisme : Horizon 2020 Framework Programme
ID : 634869
Organisme : Horizon 2020 Framework Programme
ID : 634869
Organisme : Horizon 2020 Framework Programme
ID : 634869
Organisme : Horizon 2020 Framework Programme
ID : 634869
Investigateurs
Fabrizia Lattanzio
(F)
Andrea Corsonello
(A)
Silvia Bustacchini
(S)
Silvia Bolognini
(S)
Paola D'Ascoli
(P)
Raffaella Moresi
(R)
Giuseppina Di Stefano
(G)
Cinzia Giammarchi
(C)
Anna Rita Bonfigli
(AR)
Roberta Galeazzi
(R)
Federica Lenci
(F)
Stefano Della Bella
(SD)
Enrico Bordoni
(E)
Mauro Provinciali
(M)
Robertina Giacconi
(R)
Cinzia Giuli
(C)
Demetrio Postacchini
(D)
Sabrina Garasto
(S)
Annalisa Cozza
(A)
Romano Firmani
(R)
Moreno Nacciariti
(M)
Mirko Di Rosa
(M)
Paolo Fabbietti
(P)
Références
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Clin Nutr. 2017 Feb;36(1):49-64
pubmed: 27642056
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
Nephron. 2019;141(2):105-111
pubmed: 30415254
BMC Nephrol. 2018 Oct 11;19(1):259
pubmed: 30305034
Osteoporos Int. 2014 Sep;25(9):2189-98
pubmed: 24846317
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Nephrol Dial Transplant. 2018 Feb 1;33(2):342-348
pubmed: 28340152
PLoS One. 2015 Jun 17;10(6):e0130740
pubmed: 26083479
J Gerontol A Biol Sci Med Sci. 2018 Mar 2;73(3):386-392
pubmed: 28407041
PLoS One. 2017 Apr 27;12(4):e0176230
pubmed: 28448584
Age Ageing. 2011 Jul;40(4):423-9
pubmed: 21624928
BMC Geriatr. 2019 Nov 20;19(1):318
pubmed: 31747923
Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2079-88
pubmed: 25392147
Age Ageing. 2015 Sep;44(5):807-9
pubmed: 26220989
J Am Med Dir Assoc. 2014 Feb;15(2):95-101
pubmed: 24461239
J Am Med Dir Assoc. 2011 May;12(4):249-56
pubmed: 21527165
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):253-9
pubmed: 25425503
Psychiatry Res. 1992 Mar;41(3):237-48
pubmed: 1594710
J Am Med Dir Assoc. 2011 Jul;12(6):403-9
pubmed: 21640657
J Diabetes Investig. 2017 Nov;8(6):783-787
pubmed: 28130832
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):584-90
pubmed: 24737561
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58
pubmed: 24737557
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Clin Nutr. 2015 Aug;34(4):667-73
pubmed: 25103151
Clin Nutr. 2010 Apr;29(2):154-9
pubmed: 20060626
BMC Nephrol. 2018 Oct 11;19(1):260
pubmed: 30309342
J Aging Res. 2012;2012:754739
pubmed: 22536505
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
Nephrol Dial Transplant. 2016 May;31(5):798-806
pubmed: 26932693
Age Ageing. 2019 Nov 1;48(6):910-916
pubmed: 31329815
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Age Ageing. 2019 Jan 1;48(1):48-56
pubmed: 30052707
Medicine (Baltimore). 2016 Jan;95(3):e2500
pubmed: 26817888
Nephrol Dial Transplant. 2015 Oct;30(10):1718-25
pubmed: 25999376
Eur J Clin Nutr. 2020 Apr;74(4):573-580
pubmed: 31586126
Am J Nephrol. 2007;27(3):279-86
pubmed: 17440263
Nutrients. 2018 Dec 10;10(12):
pubmed: 30544657
Age (Dordr). 2016 Dec;38(5-6):525-533
pubmed: 27566307
Int Urol Nephrol. 2017 Nov;49(11):1979-1988
pubmed: 28913589
J Am Geriatr Soc. 2016 Aug;64(8):1567-73
pubmed: 27351866
Ann Intern Med. 2012 Oct 2;157(7):471-81
pubmed: 23027318
Metabolism. 2016 Oct;65(10):1531-40
pubmed: 27621188